ArticleBMC infectious diseases2026
Prevalence and phenotypic characterization of carbapenem resistance in multidrug-resistant Gram-negative bacteria across selected healthcare facilities in the United Arab Emirates: a retrospective study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenems are essential antibiotics used to treat severe nosocomial infections. However, the misuse of these antibiotics has led to the emergence of carbapenem-resistant organisms (CROs), posing significant public health threats. This study aims to determine the prevalence and phenotypic profile of carbapenem resistance (CR) in multidrug-resistant Gram-negative bacteria (MDR-GNB) in selected healthcare facilities in the United Arab Emirates (UAE).
methodsA retrospective study was conducted across 65 healthcare facilities in Dubai and the Northern Emirates (NE) from January 2018 to June 2021. Results from GNB isolates - including Enterobacterales, Acinetobacter, and Pseudomonas aeruginosa- obtained from various clinical samples were collected and assessed for CR using CLSI guidelines at all locations. MDR-CRO prevalence was calculated within each bacterial group using total isolates of that group as the denominator at each time point.
resultsOf the 77,228 GNB collected, 3,829 (5%) MDR-CROs were identified. Within the MDR-CROs subset, Enterobacterales accounted for 65.8% (48.7% of which were Klebsiella pneumoniae), P. aeruginosa 28.6%, and Acinetobacter 5.6%. In contrast, period prevalence calculated within total isolates of each organism group was highest for MDR-CR Acinetobacter (22.8%), followed by MDR-CR P. aeruginosa (12.9%), and MDR-CR Enterobacterales (5.6%). A significant increase in MDR-CR Acinetobacter was observed in the NE in mid-2021, which coincided with the COVID-19 pandemic. Hospitals were the primary source of MDR-CR isolates, accounting for more than 90% of Acinetobacter and P. aeruginosa cases, and 62.6% of Enterobacterales cases. Carbapenems nonsusceptibility varied among bacterial species.
conclusionsThis study highlights the increasing CR burden of Acinetobacter, P. aeruginosa, and K. pneumoniae in the UAE. Regional variations in resistance, particularly the MDR-CR Acinetobacter surge in the NE during the COVID-19 pandemic, stress the need for tailored infection control measures and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.